Reuters logo
BRIEF-Regeneron and Sanofi announce Kevzara license application resubmission for review by FDA
2017年4月28日 / 早上6点15分 / 7 个月前

BRIEF-Regeneron and Sanofi announce Kevzara license application resubmission for review by FDA

April 28 (Reuters) - Sanofi

* Regeneron and Sanofi announce Kevzara® (sarilumab) Biologics License Application resubmission accepted for review by U.S. FDA

* Per Prescription Drug User Fee Act (PDUFA), new target action date is May 22, 2017

* European Commission expected to make a final decision on marketing authorization application for Kevzara in EU in coming months Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below